A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma

Inclusion criteria

• Has the ability to understand and willingness to sign a written informed consent form.
• Male or female from 18 years of age or older.
• Histologically confirmed locally advanced or metastasis clear cell renal cell carcinoma.
• Has at least one measurable lesion per RECIST v1.1.
• Has a life expectancy of ≥ 12 weeks.
• Adequate organ function.

Exclusion criteria

• Patients with known active CNS metastases and/or cancerous meningitis.
• Has received any type of systemic anticancer monoclonal antibodies or other immunosuppressants within 4 weeks prior to the first dose. Has received prior chemotherapy, targeted therapy, or other investigational therapy within 2 weeks prior to the first dose.
• Has failed to recover from a ≥ grade 2 adverse event due to prior anti-tumor therapy.
• Has impaired heart function,or clinically significant cerebrovascular and cardiovascular disease.
• Subjects with dysphagia or known drug absorption disorders.
• Has a history of any other malignancy within 5 years.
• Has severe oncological complications.
• Is currently participating in other clinical studies.
• Subjects with be unsuitable for participation in the trial evaluated by investigator.